| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.WNEU.2013.01.131 |
| P698 | PubMed publication ID | 23416769 |
| P50 | author | Yasin Temel | Q28839725 |
| Ali Jahanshahi | Q64995250 | ||
| P2093 | author name string | Ruth Fleischeuer | |
| David Creytens | |||
| Youssef Yakkioui | |||
| Jacobus J Van Overbeeke | |||
| René G C Santegoeds | |||
| P2860 | cites work | Interaction between Cdc37 and Cdk4 in human cells | Q24321275 |
| Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway | Q24648029 | ||
| Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation | Q24651310 | ||
| Crystal structure of human CDK4 in complex with a D-type cyclin | Q24656160 | ||
| Live or let die: the cell's response to p53 | Q29547663 | ||
| Cancer. p53, guardian of the genome | Q29615610 | ||
| Functional interactions of the retinoblastoma protein with mammalian D-type cyclins | Q29618856 | ||
| Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients | Q33270830 | ||
| Skull base chordomas: correlation of tumour doubling time with age, mitosis and Ki67 proliferation index | Q33270925 | ||
| Chordoma: incidence and survival patterns in the United States, 1973-1995. | Q33270957 | ||
| Chordoma: review of clinicoradiological features and factors affecting survival | Q33271158 | ||
| Apoptotic and proliferative markers in chordomas: a study of 26 tumors | Q33271245 | ||
| Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability | Q33271977 | ||
| Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression | Q33272380 | ||
| Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams | Q33272423 | ||
| Chordomas of the skull base: follow-up review and prognostic factors | Q33272570 | ||
| Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis | Q33273006 | ||
| Proton therapy in chordoma of the base of the skull: a systematic review | Q33273341 | ||
| Adjuvant radiation therapy and chondroid chordoma subtype are associated with a lower tumor recurrence rate of cranial chordoma | Q33273597 | ||
| Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. | Q33273688 | ||
| Loss of SMARCB1/INI1 expression in poorly differentiated chordomas | Q33273964 | ||
| Chordoma: role of radiation therapy | Q33276967 | ||
| Chordoma and chondroid neoplasms of the spheno-occiput: An immunohistochemical study of 41 cases with prognostic and nosologic implications | Q33278408 | ||
| Base of skull chordoma. A correlative study of histologic and clinical features of 62 cases | Q33278482 | ||
| Chordomas of the mediastinum: clinicopathologic, immunohistochemical, and ultrastructural study of six cases presenting as posterior mediastinal masses | Q33278670 | ||
| Proliferative activities in conventional chordoma: a clinicopathologic, DNA flow cytometric, and immunohistochemical analysis of 17 specimens with special reference to anaplastic chordoma showing a diffuse proliferation and nuclear atypia | Q33278726 | ||
| Chordoma: long-term follow-up after radical photon irradiation | Q33278855 | ||
| Immunohistochemical examination of proliferative potentials and the expression of cell cycle-related proteins of intracranial chordomas | Q33278919 | ||
| Dedifferentiated chordoma: a case report | Q33279129 | ||
| The p53 tumor suppressor gene: from molecular biology to clinical investigation. | Q33981374 | ||
| The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor | Q34030117 | ||
| Structure of an Hsp90-Cdc37-Cdk4 complex. | Q34562863 | ||
| Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro | Q35841926 | ||
| Therapeutic targets in the ARF tumor suppressor pathway. | Q36879301 | ||
| CDK4 inhibitors and apoptosis: a novel mechanism requiring nucleolar targeting of RelA. | Q40128010 | ||
| Docking-dependent regulation of the Rb tumor suppressor protein by Cdk4. | Q40550671 | ||
| Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4. | Q40602791 | ||
| Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16. | Q41982097 | ||
| Phosphorylation of p16INK4A correlates with Cdk4 association | Q44279182 | ||
| Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53. | Q45864245 | ||
| Cyclin-dependent kinases regulate the antiproliferative function of Smads | Q47229633 | ||
| Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas. | Q55474435 | ||
| p53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrest | Q72534970 | ||
| Chordoma | Q74039855 | ||
| p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products | Q74183048 | ||
| The over-expression of p53 H179Y residue mutation causes the increase of cyclin A1 and Cdk4 expression in HELF cells | Q80387675 | ||
| P433 | issue | 1-2 | |
| P921 | main subject | chordoma | Q1076389 |
| base of skull | Q1423729 | ||
| P304 | page(s) | e311-8 | |
| P577 | publication date | 2013-02-14 | |
| P1433 | published in | World Neurosurgery | Q26853866 |
| P1476 | title | A comparison of cell-cycle markers in skull base and sacral chordomas | |
| P478 | volume | 82 |
| Q47384424 | CDK4 expression in chordoma: A potential therapeutic target |
| Q33275783 | Chordoma: an update on the pathophysiology and molecular mechanisms |
| Q41184358 | EGFR Inhibition in a Pretreated Sacral Chordoma: A Role for Erlotinib? Case Report and a Brief Review of Literature |
| Q50128933 | Immunophenotypic features of dedifferentiated skull base chordoma: An insight into the intratumoural heterogeneity |
| Q33275755 | In chordoma, metastasis, recurrences, Ki-67 index, and a matrix-poor phenotype are associated with patients' shorter overall survival |
| Q50988142 | Ki-67 Index as a Prognostic Marker in Chordomas: A Systematic Review of the Literature. |
| Q33275854 | Prognostic and Therapeutic Markers in Chordomas: A Study of 287 Tumors |
| Q98184286 | Synergistic drug combinations and machine learning for drug repurposing in chordoma |
| Q92559641 | The clinical outcomes for chordomas in the cranial base and spine: A single center experience |
| Q33275745 | The molecular aspects of chordoma |
Search more.